CA 50 and CA 19-9 antigen expression in normal, hyperplastic, and neoplastic thyroid tissue.
The occurrence of the tumor-associated carbohydrate antigens defined by the monoclonal antibodies (moabs) C 50 and 19-9 has been studied by immunoperoxidase staining of formalin-fixed and paraffin-embedded tissue specimens from normal, hyperplastic, adenomatous, and carcinomatous thyroid tissues. Epithelial expression of these antigens was observed neither in normal nor in hyperplastic thyroid tissue. The antigens were expressed in only 1 of 26 follicular adenomas and the staining in this case was weak and restricted to a few cells. In contrast, the expression of this antigens is marked and progressive in carcinomatous tissues. A high proportion, 48 of 52 papillary carcinomas demonstrated C 50 reactivity, whereas 25 of these tumors expressed the CA 19-9 antigen. Of 25 follicular carcinomas, 15 gave a positive staining for the CA 50 and 6 for the CA 19-9 antigen. CA 50 antigen expression was still detected in tumor cells lacking the CA 19-9 antigen and C 50 reactive material was found in all tissue specimens from medullary carcinomas tested, whereas CA 19-9 antigen staining was consistently negative. This indicates that the moab C 50 which reacts, like the moab 19-9, with the sialylated Lewisa (Lea) blood group determinant also binds to other antigens apart from the sialylated Lea in CA 19-9 antigen negative tumor cells. Although, the functional significance of CA 50 and CA 19-9 antigen expression remains to be investigated, these results suggest that the demonstration of these antigens could provide additional differential diagnostic parameters for the characterization of hyperplastic and neoplastic lesions of the thyroid gland. Further clinical studies will show whether these carbohydrate antigens are useful serum markers for the monitoring of thyroid carcinomas.
Vierbuchen
M
M
Institute of Pathology, University of Cologne.
Schröder
S
S
Uhlenbruck
G
G
Ortmann
M
M
Fischer
R
R
D000230:Adenocarcinoma / Q000276:immunology; D000236:Adenoma / Q000276:immunology; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis*; D002277:Carcinoma / Q000276:immunology; D002291:Carcinoma, Papillary / Q000276:immunology; D006801:Humans; D006965:Hyperplasia; D007150:Immunohistochemistry; D013959:Thyroid Diseases / Q000276:immunology*; D013961:Thyroid Gland / Q000276:immunology*; D013964:Thyroid Neoplasms / Q000276:immunology*
D015295:Antigens, Tumor-Associated, Carbohydrate